Reid Hoffman Leaves Microsoft Board to Lead AI Drug Discovery Startup Manus

Manus launched in early 2025 with a clear mission: harness artificial intelligence to accelerate drug discovery, especially in cancer treatment. Reid Hoffman, stepping down from Microsoft’s board in June 2026, co-founded the startup and now chairs its board. The CEO, Dr. Siddhartha Mukherjee, brings a strong medical research background, aiming to push AI beyond routine data analysis into creative chemistry design. The company claims its AI models can identify novel molecular structures faster than traditional methods. Manus leverages deep learning to predict how compounds interact with biological targets, speeding up the early stages of drug development. Their approach focuses on generating candidate molecules that might evade common pitfalls in drug design, such as toxicity or poor bioavailability. Manus quickly attracted attention, raising over $50 million in venture funding by mid-2026. Investors see potential in combining Hoffman’s tech expertise with Mukherjee’s clinical insight. The startup’s progress so far includes partnerships with academic labs and pharmaceutical firms to validate AI-generated compounds. While the field is crowded with AI drug discovery firms, Manus aims to differentiate itself through proprietary algorithms and a tight integration of AI with experimental feedback loops. The company’s work remains under close watch, as the challenge lies not only in designing molecules but also in translating them into effective therapies.